Pioglitazone Attenuates Reoxygenation Injury in Renal Tubular NRK-52E Cells Exposed to High Glucose Inhibiting Oxidative Stress and Endoplasmic Reticulum Stress
Overview
Affiliations
Renal ischemia-reperfusion injury is a major cause of acute kidney injury. In the present study, we investigated the effects of pioglitazone on hypoxia/reoxygenation (H/R) injury in rat renal tubular epithelial cells (RTECs) under normal- (NG) or high-glucose (HG) culture conditions evaluating oxidative stress and endoplasmic reticulum stress (ERS). The RTECs (NRK-52E cells) were divided into six groups as follows: NG group, HG group, NG + H/R group, HG + H/R group, NG + Pio + H/R group, and HG + Pio + H/R group, among which cells in H/R groups were subjected to 4 h of hypoxia followed by 12 h of reoxygenation. After that, the cells were evaluated using the Cell Counting Kit-8 assay for the determination of their viability and flow cytometry assay for the detection of apoptosis. The levels of superoxide dismutase (SOD), glutathione reductase (GSH), catalase (CAT), and malondialdehyde (MDA) were determined colorimetric chemical assays. In addition, the expression of ERS-associated proteins, i.e. ATF4, ATF6, GRP78, and CHOP, was determined western blotting. A HG environment could reduce the viability and increase the apoptotic rate of NRK-52E cells with increased MDA levels and decreased SOD, CAT, and GSH levels, and upregulate the expression of ERS-associated proteins, i.e. ATF4, ATF6, and GRP78. H/R injury could further aggravate changes in the above indicators, but pioglitazone could significantly reverse such changes and alleviate cell injury. Thus, Pioglitazone exhibits a cytoprotective effect on RTECs against H/R injury under NG or HG culture conditions by inhibiting oxidative stress and ERS.
Golmohammadi M, Sadeghi Ivraghi M, Hasan E, Huldani H, Zamanian M, Rouzbahani S Clin Exp Nephrol. 2024; 28(10):955-968.
PMID: 38935212 DOI: 10.1007/s10157-024-02525-3.
Ye Z, Zhang J, Xu Z, Li Z, Huang G, Tong B Hum Cell. 2024; 37(4):959-971.
PMID: 38607518 DOI: 10.1007/s13577-024-01059-w.
Prosthetic vascular grafts engineered to combat calcification: Progress and future directions.
Brown T, Alharbi S, Ho K, Jiang B Biotechnol Bioeng. 2022; 120(4):953-969.
PMID: 36544433 PMC: 10023339. DOI: 10.1002/bit.28316.
Pioglitazone in diabetic kidney disease: forgotten but not gone.
Papaetis G Arch Med Sci Atheroscler Dis. 2022; 7:e78-e93.
PMID: 36158067 PMC: 9487837. DOI: 10.5114/amsad/151046.
Zhou Q, He X, Zhao X, Fan Q, Lai S, Liu D Oxid Med Cell Longev. 2022; 2022:3737137.
PMID: 36092159 PMC: 9458375. DOI: 10.1155/2022/3737137.